The local medical sector is excited with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor showing impressive results in early trials for managing obesity. This therapy promises a https://health-lists.com/story22605965/retatrutide-australia-a-new-solution-for-obesity-treatment